Monday, January 12, 2009

If this is what the FDA approves...

Yikes, look at what the FDA approves--strong hormones for "vaginal atrophy." May cause blindness, but hey, your lady parts will look better!:
------------------------------------------------

On November 28, the FDA approved synthetic conjugated estrogens-A 0.625 mg/g vaginal cream (SCE-A Vaginal Cream; Duramed Pharmaceuticals, Inc) for the treatment of moderate to severe vaginal dryness and moderate to severe dyspareunia, which are both symptoms of vulvar and vaginal atrophy due to menopause. SCE-A vaginal cream is administered intravaginally at a recommended dose of 1 g daily for 1 week, followed by a 1-g intravaginal dose twice a week.

SCE-A vaginal cream contains a blend of 9 plant-derived estrogenic substances in a nonliquefying base. According to a company news release, the product is designed to complement Duramed's existing line of therapies for postmenopausal symptoms.

The approval was based on data from a randomized, double-blind, placebo-controlled, multicenter study (n = 275), showing that SCE-A vaginal cream was significantly more effective than placebo for reduction of symptoms of vaginal dryness (P = .0016) and dyspareunia (P = .0002) during a 12-week period.

Other significant results included a mean increase in superficial cells (25.9% SCE-A vs 3.8% placebo), a mean decrease in parabasal cells (36.3% SCE-A vs 5.7% placebo), and a mean reduction in pH (1.47 SCE-A vs 0.30 placebo).

Common adverse effects include headache, vulvovaginal infection, upper respiratory tract infection, and hot flashes. Because the use of unopposed estrogens increases the risk for endometrial cancer, a progestin should be considered for postmenopausal women with a uterus who are treated with an estrogen. The addition of a progestin has been shown to reduce the risk for endometrial hyperplasia, a potential precursor to endometrial cancer, in women taking estrogen therapy.

Estrogen therapy also has been shown to increase the risk for gallbladder disease, and probable dementia in women older than 65 years of age. Women who are also receiving thyroid hormone replacement therapy should be monitored, and estrogen therapy should be discontinued in women who develop severe hypercalcemia, loss of vision, severe hypertriglyceridemia, or cholestatic jaundice.

3 comments:

Anonymous said...

I'm all for green fertility, but do your research before you post a "YIKES!" This is class labeling applied to ALL ESTROGENS including non-regulated bioidentical estrogens. The language you put in bold type has everything to do with the FDA covering their bases and nothing to do with what is actually discovered in trials.

Anonymous said...

喝花酒
酒店喝酒
暑假打工
寒假打工
酒店小姐
酒店兼職
禮服店
酒店經紀
酒店兼差
酒店
酒店經紀人
酒店現領
酒店經紀爆米花
酒店經紀
酒店打工
酒店上班
假日打工
台北酒店經紀
酒店pt
酒店pt
酒店應酬
粉味
酒店經紀PRETTY GIRL
酒店經濟
酒店經濟
晚上兼差

MonstrousEgotist said...

This company has finally gotten FDA approval for a topical estrogen made from PLANTS instead of from PREgnant MAre uRINe and NOW you're saying YIKES!?!?!? Seems to me like a company has been doing something right for once!
Don't leave me signed as "Anonymous",
my name is Donna, and I've been suffering from the symptoms that go along with surgical menopause for years, but can't/won't use HRT - until now.